Illumina, Inc. (NASDAQ:ILMN) Stock Position Reduced by RTW Investments LP

RTW Investments LP lessened its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 33.3% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 376,250 shares of the life sciences company’s stock after selling 188,125 shares during the period. Illumina comprises 1.8% of RTW Investments LP’s portfolio, making the stock its 23rd largest position. RTW Investments LP owned 0.24% of Illumina worth $87,497,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the company. CenterBook Partners LP lifted its holdings in Illumina by 336.0% during the 1st quarter. CenterBook Partners LP now owns 22,123 shares of the life sciences company’s stock worth $5,145,000 after buying an additional 17,049 shares during the last quarter. Macquarie Group Ltd. lifted its holdings in shares of Illumina by 0.6% in the 1st quarter. Macquarie Group Ltd. now owns 107,836 shares of the life sciences company’s stock worth $25,077,000 after purchasing an additional 620 shares during the last quarter. Mirova bought a new stake in shares of Illumina in the 1st quarter worth approximately $175,000. Veritable L.P. lifted its holdings in shares of Illumina by 4.1% in the 1st quarter. Veritable L.P. now owns 9,053 shares of the life sciences company’s stock worth $2,105,000 after purchasing an additional 353 shares during the last quarter. Finally, Prospera Financial Services Inc lifted its holdings in shares of Illumina by 22.8% in the 1st quarter. Prospera Financial Services Inc now owns 2,318 shares of the life sciences company’s stock worth $539,000 after purchasing an additional 430 shares during the last quarter. Institutional investors own 92.17% of the company’s stock.

Illumina Price Performance

Shares of ILMN stock traded down $0.49 during mid-day trading on Friday, hitting $158.36. 1,552,224 shares of the stock traded hands, compared to its average volume of 1,285,987. Illumina, Inc. has a twelve month low of $156.14 and a twelve month high of $248.87. The firm has a market cap of $25.07 billion, a price-to-earnings ratio of -5.95, a price-to-earnings-growth ratio of 8.58 and a beta of 1.12. The company’s 50-day simple moving average is $178.04 and its 200-day simple moving average is $198.77. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.13 and a current ratio of 1.40.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Wednesday, August 9th. The life sciences company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.30. Illumina had a positive return on equity of 1.97% and a negative net margin of 93.86%. The company had revenue of $1.18 billion for the quarter, compared to analysts’ expectations of $1.16 billion. During the same period last year, the firm earned $0.57 EPS. The firm’s revenue for the quarter was up 1.2% on a year-over-year basis. As a group, equities research analysts expect that Illumina, Inc. will post 0.83 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Robert W. Baird cut their price target on Illumina from $229.00 to $180.00 in a report on Thursday, August 10th. Evercore ISI reissued an “outperform” rating and issued a $240.00 price target on shares of Illumina in a report on Friday, September 1st. UBS Group cut their price target on Illumina from $240.00 to $230.00 and set a “neutral” rating on the stock in a report on Tuesday, August 8th. Citigroup cut their price target on Illumina from $180.00 to $150.00 and set a “sell” rating on the stock in a report on Thursday, August 10th. Finally, Stifel Nicolaus cut their price target on Illumina from $265.00 to $225.00 and set a “buy” rating on the stock in a report on Thursday, August 10th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $236.05.

Insider Activity

In other news, SVP Susan H. Tousi sold 500 shares of Illumina stock in a transaction on Thursday, June 22nd. The stock was sold at an average price of $200.00, for a total transaction of $100,000.00. Following the transaction, the senior vice president now directly owns 46,522 shares in the company, valued at approximately $9,304,400. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In the last ninety days, insiders have sold 1,500 shares of company stock worth $278,560. 0.13% of the stock is owned by company insiders.

Illumina Company Profile

Illumina, Inc develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; and whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.